ID: ALA367313

Max Phase: Preclinical

Molecular Formula: C28H37N5O5

Molecular Weight: 523.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1oc([C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)N2CCCCCC2)nc1C(=O)O

Standard InChI:  InChI=1S/C28H37N5O5/c1-17(2)14-22(31-28(37)33-12-8-4-5-9-13-33)25(34)30-23(26-32-24(27(35)36)18(3)38-26)15-19-16-29-21-11-7-6-10-20(19)21/h6-7,10-11,16-17,22-23,29H,4-5,8-9,12-15H2,1-3H3,(H,30,34)(H,31,37)(H,35,36)/t22-,23+/m0/s1

Standard InChI Key:  XWIKGWWJRNWKJJ-XZOQPEGZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 523.63

Molecular Weight (Monoisotopic): 523.2795

AlogP: 4.56

#Rotatable Bonds: 9

Polar Surface Area: 140.56

Molecular Species: ACID

HBA: 5

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.75

CX Basic pKa:

CX LogP: 3.63

CX LogD: 0.34

Aromatic Rings: 3

Heavy Atoms: 38

QED Weighted: 0.32

Np Likeness Score: -0.62

References

1. von Geldern TW, Hutchins C, Kester JA, Wu-Wong JR, Chiou W, Dixon DB, Opgenorth TJ..  (1996)  Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.,  39  (4): [PMID:8632419] [10.1021/jm950591h]

2. von Geldern TW, Kester JA, Bal R, Wu-Wong JR, Chiou W, Dixon DB, Opgenorth TJ..  (1996)  Azole endothelin antagonists. 2. Structure-activity studies.,  39  (4): [PMID:8632420] [10.1021/jm950592+]

Source

Source(1):

• Scientific Literature